Evidence map›Paper›PMID 35737114›Full record

ArticleCellular and molecular life sciences : CMLS2022

Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma.

Victor O Oria, Hongyi Zhang, Christopher R Zito, Chetan K Rane, Xian-Yong Ma, Olivia K Provance, Thuy T Tran, Adebowale Adeniran, Yuval Kluger, Mario Sznol and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Murine Cell Line Models for Vascular Mimicry: The Role of YAP/TAZ Signaling.International journal of molecular sciences · 2025
    Article
  4. Review
  5. Vascular mimicry as a facilitator of melanoma brain metastasis.Cellular and molecular life sciences : CMLS · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Victor O OriaSection of Medical Oncology, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, SHM234E, New Haven, CT, 06520, USA.
Hongyi ZhangSection of Medical Oncology, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, SHM234E, New Haven, CT, 06520, USA.
Christopher R ZitoSection of Medical Oncology, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, SHM234E, New Haven, CT, 06520, USA.
Chetan K RaneSection of Medical Oncology, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, SHM234E, New Haven, CT, 06520, USA.
Xian-Yong MaSection of Medical Oncology, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, SHM234E, New Haven, CT, 06520, USA.
Olivia K ProvanceSection of Medical Oncology, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, SHM234E, New Haven, CT, 06520, USA.
Thuy T TranSection of Medical Oncology, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, SHM234E, New Haven, CT, 06520, USA.
Adebowale AdeniranDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Yuval KlugerDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Mario SznolSection of Medical Oncology, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, SHM234E, New Haven, CT, 06520, USA.
Marcus W BosenbergDepartment of Dermatology, Yale University School of Medicine, New Haven, CT, USA.
Harriet M KlugerSection of Medical Oncology, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, SHM234E, New Haven, CT, 06520, USA.
Lucia B JilaveanuSection of Medical Oncology, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, SHM234E, New Haven, CT, 06520, USA. lucia.jilaveanu@yale.edu.ORCID http://orcid.org/0000-0001-8900-5083
Yale University · USJinan University · CNUniversity of Copenhagen · DKUniversity of Saint Joseph · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NRSA Training CoreTL1TR001864 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$9.9M
YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAMK12CA215110 · NCI · YALE UNIVERSITY · PI Harriet M. Kluger · 2018 to 2026
$6.1M
Yale University Clinical and Translational Science Award ProgramKL2TR000140 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$2.9M
Renalase inhibition for treatment of unresectable melanomaR01CA216846 · NCI · YALE UNIVERSITY · PI DESIR, GARY V., KLUGER, HARRIET M. · 2017 to 2021
$2.4M
Inherent tropism and/or immune modulation in melanoma brain metastasisR01CA204002 · NCI · YALE UNIVERSITY · PI JILAVEANU, LUCIA BEATRICE · 2017 to 2021
$1.9M
American Cancer Society 130157-RSG-16-216-01-TBGMelanoma Research Alliance #308721NCATS NIH HHS KL2 TR000140NCATS NIH HHS TL1 TR001864NCATS NIH HHS UL1 TR001863NCI NIH HHS K12 CA215110NCI NIH HHS K12CA215110NCI NIH HHS R01 CA204002NCI NIH HHS R01CA204002NCI NIH HHS R01 CA216846NIH HHS KL2 TR000140
6 · The paper itself

Abstract

We aimed to study mechanisms controlling metastatic outgrowth of melanoma into clinically relevant lesions, a critical process responsible for the majority of melanoma deaths. To this end, we developed novel in vivo models and identified molecular events that can be ascribed to their distinct phenotypes, indolent or highly metastatic. Induction of a proliferative state at distant sites was associated with high levels of the stem-like/progenitor marker, SOX2, and required the upregulation of FMOD, an extracellular matrix component, which modulates tumor-stroma interactions. Functional studies revealed a possible link between FMOD and SOX2; dual FMOD and SOX2 silencing nearly abolished brain metastasis and had a similar effect on distant metastasis to other sites. Our in vitro data suggests that FMOD and SOX2 cooperation plays an important role in tumor vasculogenic mimicry. Furthermore, we found that FMOD and SOX2 functional roles might converge at the activation of transcriptional co-factors YAP and TAZ, possibly via crosstalk with the tumor suppressor Hippo pathway. Finally, high expression of both genes in patient specimens predicted early development of brain metastasis. Thus, our study identifies FMOD and SOX2 cooperation as a novel regulatory mechanism that might be linked functionally to melanoma metastatic competence.

Indexed as

MelanomaBrain NeoplasmsFibromodulinHumansNeoplasm MetastasisSignal TransductionSOXB1 Transcription FactorsTranscription FactorsFibromodulinSOX2 protein, humanSOXB1 Transcription FactorsTranscription FactorsBrain metastasisExtracellular matrixFMODHippo pathwayVasculogenic mimicry

Identifiers

PMID35737114
PMCPMC9226089
OpenAlexW4283328309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.